Cisplatin, vinblastine, and bleomycin as second-trial therapy in ovarian carcinoma. A pilot study of the Gynecologic Oncology Group.

Stehman FB, Ehrlich CE, Williams SD, Einhorn LH
American journal of clinical oncology · 1985 · doi:10.1097/00000421-198502000-00041 · PMID:2581434
OA: closed
Full text JSON View on PubMed View at publisher
⚙ AI-generated summary by qwen3.7-flash, 2026-08-28 ⓘ

This pilot study evaluated cisplatin, vinblastine, and bleomycin as second-line therapy for ovarian carcinoma, finding objective responses in half of the patients despite significant hematologic toxicity and one treatment-related death.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

⚙ AI-generated deep summary by qwen3.7-flash, 2026-08-27 · read from full text ⓘ

This pilot study by the Gynecologic Oncology Group evaluated the efficacy and toxicity of cisplatin, vinblastine, and bleomycin as second-line therapy for ten patients with ovarian carcinoma that had progressed on initial chemotherapy. The regimen demonstrated objective responses in half of the participants, including three complete and two partial remissions, although significant hematologic toxicity was observed, particularly at higher vinblastine doses. Bleomycin-induced pulmonary fibrosis resulted in one patient death, highlighting substantial risks associated with the treatment protocol. This paper is centrally about ovarian cancer rather than endometriosis or adenomyosis; it was included in the corpus via a keyword match in the upstream search index.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Abstract

Ten patients with ovarian carcinoma whose tumors had progressed on first-trial chemotherapy were treated with cisplatin, vinblastine, and bleomycin (PVB) to determine the efficacy, dose range, and toxicity of this combination. Two dose levels of vinblastine were used. Objective responses occurred in 5/10 patients (3 CR, 2 PR), with a median response duration of 17.0 weeks. Toxicity was appreciable. One patient expired of bleomycin-induced pulmonary fibrosis. With the higher dose of vinblastine, four patients had grade III and three patients had grade IV hematologic toxicity. At the lower dose, two patients had grade II and one patient had grade III hematologic toxicity. PVB has activity in second-trial therapy of ovarian carcinoma at the dose and schedule tested, but the role of this regimen in the future treatment of this disease remains to be determined.
Full text 1,087 characters · extracted from oa-doi-fallback · click to expand
Cisplatin, vinblastine, and bleomycin as second-trial therapy in ovarian carcinoma A pilot study of the Gynecologic Oncology Group - Frederick B. Stehman - Clarence E. Ehrlich - Stephen D. Williams - Lawrence H. Einhorn TEN PATIENTS WITH OVARIAN CARCINOMA WHOSE TUMORS HAD PROGRESSED on first-trial chemotherapy were treated with cisplatin, vinblastine, and bleomycin (PVB) to determine the efficacy, dose range, and toxicity of this combination. Two dose levels of vinblastine were used. Objective responses occurred in 5/10 patients (3 CR, 2 PR), with a median response duration of 17.0 weeks. Toxicity was appreciable. One patient expired of bleomycin-induced pulmonary fibrosis. With the higher dose of vinblastine, four patients had grade III and three patients had grade IV hematologic toxicity At the lower dose, two patients had grade II and one patient had grade III hematologic toxicity. PVB has activity in second-trial therapy of ovarian carcinoma at the dose and schedule tested, but the role of this regimen in the future treatment of this disease remains to be determined.

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

⚙ Ask this paper AI returns verbatim quotes from the full text · source: oa-doi-fallback ⓘ

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.

Source provenance

europepmc
last seen: 2026-10-04T09:26:46.659050+00:00
unpaywall
last seen: 2026-10-04T06:29:23.997191+00:00